CAS: 154-69-8; N1-Benzyl-N2,N2-Dimethyl-N1-(Pyridin-2-yl)Ethane-1,2-Diamine Hydrochloride

该化合物是化学配方C18H22ClN的抗脊髓灰质炎,主要用于缓解过敏反应和症状,如干热和尿液,具有第一代抗脊髓灰质炎的作用,这意味着它可以跨越血液脑屏障,常常导致镇静作用.该物质似乎是白色的,可溶解于水和酒精,适合各种药物配方.其行动机制包括阻塞H1甲胺受体,从而减少体内的甲胺影响.Triterennamine也因其抗胆碱性能而著称,这可能导致副作用,如干嘴,干燥和晕眩等.由于镇静剂的影响,在使用机器或用完之后驾驶时要小心谨慎.与任何药物一样,必须在医疗监督下使用三氟硝基盐酸来控制潜在的副作用和与其他药物的相互作用.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-12295961-B2
    优先权日:2009-12-31
    标 题:Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
    发明人:DHINGRA OM
    权利人:MARIUS PHARMACEUTICALS INC
    摘要:A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

    专利号:US-2003138490-A1
    优先权日:2001-09-08
    标 题 :Synthesis and uses of polymer gel nanoparticle networks
    发明人:HU ZHIBING; LU XIHUA; GAO JUN; PONDER BILL C; JOHN JOHN ST; MORO DANIEL G
    摘要:Disclosed is a new class of nanostructured polymeric materials comprising polymer gel nanoparticles that are covalently bonded through functional groups on the surfaces of neighboring particles. These nanoparticles may be prepared as suspensions in an aqueous or, non-aqueous environment. These gels have two unique and different structural networks; the primary network comprises crosslinked polymer chains in each individual particle, while the secondary network is a system of crosslinked nanoparticles. Particular polymer gel nanoparticle network compositions disclosed herein may function as carriers for controlled delivery of pharmaceuticals or other chemical agents, gel sensors and other commercial applications.

    专利号:US-11617758-B2
    优先权日:2009-12-31
    标 题 :Emulsion formulations
    发明人:DHINGRA OM; BERNSTEIN JAMES S
    权利人:MARIUS PHARMACEUTICALS LLC
    摘要:A SEDDS or SMEDDS or SNEDDS formulation for drug delivery of a lipophilic therapeutic agent, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of the therapeutic agent by formulation with a lipophilic surfactant, a hydrophilic surfactant, one or more solubilizers and, optionally, digestible oils, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such therapeutic agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

    专利号:US-2013303495-A1
    优先权日:2009-12-31
    标题:Emulsion formulations
    发明人:DHINGRA OM; BERNSTEIN JAMES S
    权利人:SOV THERAPEUTICS; DIFFERENTIAL DRUG DEV ASSOCIATES LLC
    摘要:A SEDDS or SMEDDS or SNEDDS formulation for drug delivery of a lipophilic therapeutic agent, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of the therapeutic agent by formulation with a lipophilic surfactant, a hydrophilic surfactant, one or more solubilizers and, optionally, digestible oils, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such therapeutic agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

    专利号:EP-1930323-A1
    优先权日:2004-03-11
    标 题:Biphenyl compounds useful in the synthesis of muscarinic receptor antagonists

    专利号:EP-1930323-B1
    优先权日:2004-03-11
    标 题:Biphenyl compounds useful in the synthesis of muscarinic receptor antagonists

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Tripelennamine. 2025 Sep 15. 39(6):669-76. doi: 10.1038/clpt.1986.117. 1(7026):885-6. doi: 10.1016/s0140-6736(58)91632-5. 39(7):e4815. doi: 10.1002/bio.4815. 235(3):683-9. 17(4):789-95. doi: 10.1016/0091-3057(82)90362-8. 229(1):214-7. 5(4):71-83. doi: 10.1300/J251v05n04_06. 158(4):261. doi: 10.1001/jama.1955.02960040019006. 4(6):937. 29(2):397-401. doi: 10.1016/0091-3057(88)90175-x. 33(1):245-51. doi: 10.1016/0091-3057(89)90457-7. 36(3):547-54. doi: 10.1016/0091-3057(90)90254-f. 1(2):161-167. 33(3):717-20. doi: 10.1016/0091-3057(89)90414-0. 34(2):149-53. doi: 10.1016/0024-3205(84)90585-x. 19(16):911-5. doi: 10.1016/0091-3057(83)90389-1. 16(3):267-9. doi: 10.1016/0031-9384(76)90131-1. 169(1):153-7. doi: 10.1016/0014-2999(89)90827-3.
    69:112-7. doi: 10.14219/jada.archive.1964.0260.

    合成参考文献


    摘要:Journal of Pharmacology and Experimental Therapeutics., 113(72), 1955 []
    摘要:Journal of Pharmacology and Experimental Therapeutics., 92(249), 1948
    摘要:Journal of Allergy., 27(57), 1956 []
    摘要:Bulletin of the Johns Hopkins Hospital., 81(55), 1947
    摘要:Proceedings of the Society for Experimental Biology and Medicine., 78(708), 1951 []
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知